Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.38
-2.15 (-0.94%)
AAPL  277.18
-1.60 (-0.58%)
AMD  220.15
+2.18 (1.00%)
BAC  53.77
-0.18 (-0.32%)
GOOG  313.30
-8.79 (-2.73%)
META  669.99
-3.43 (-0.51%)
MSFT  490.91
+7.75 (1.60%)
NVDA  183.43
+1.02 (0.56%)
ORCL  219.65
+2.06 (0.95%)
TSLA  438.37
-16.63 (-3.65%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.